Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated therapeutics for the treatment of skin diseases. Our current pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, cutaneous t-cell lymphoma and psoriasis.
Brickell Announces Confirmatory Phase 2b Study Results Presented at the 76th American Academy of Dermatology Annual Meeting at the Late-Breaking Research Forum.
Brickell Announces Positive, Statistically Significant Results of its Confirmatory Phase 2b Study of Sofpironium Bromide for the Topical Treatment of Primary Axillary Hyperhidrosis.